Brief: Aclaris Therapeutics Announces Positive Results From Phase 1 Trial Of Ati-2138, An Investigational Oral Covalent Itk/Jak3 Inhibitor
18/09/2023 12:17
Sept 18 (Reuters) - Aclaris Therapeutics Inc ACRS.O :
* ACLARIS THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE
1
MULTIPLE ASCENDING DOSE TRIAL OF ATI-2138, AN INVESTIGATIONAL
ORAL COVALENT ITK/JAK3 INHIBITOR
* ACLARIS THERAPEUTICS INC- ATI-2138 WAS GENERALLY WELL
TOLERATED
AT ALL DOSES TESTED IN TRIAL
Source text for Eikon: ID:nGNX2ypknw
Further company coverage: ACRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics Q1 net loss widens on higher R&D spending
Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055
Brief: Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
Aclaris Q4 loss narrows, but misses analysts' expectations